Cocrystal Pharma
COCP
18 hedge funds and large institutions have $6.41M invested in Cocrystal Pharma in 2019 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 7 increasing their positions, 6 reducing their positions, and 4 closing their positions.
17% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 6
0.02% less ownership
Funds ownership: 0.74% → 0.72% (-0.02%)
9% less capital invested
Capital invested by funds: $7.01M → $6.41M (-$599K)
14% less funds holding
Funds holding: 21 → 18 (-3)
75% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WA
Wasatch Advisors
Salt Lake City,
Utah
|
+$147K |
| 2 |
Dimensional Fund Advisors
Austin,
Texas
|
+$94.1K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$38K |
| 4 |
BlackRock
New York
|
+$11.6K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$2.35K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$29.7K |
| 2 |
Fifth Third Bancorp
Cincinnati,
Ohio
|
-$23K |
| 3 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
-$11.1K |
| 4 |
Jane Street
New York
|
-$6.24K |
| 5 |
NSIM
North Star Investment Management
Chicago,
Illinois
|
-$6K |
COCP Hedge Fund Activity: Q2 2019 in Review
18 of the 4,625 institutional investors tracked by Wall St. Rank reported a position in Cocrystal Pharma (COCP) for Q2 2019, worth a combined $6.41M — down 8.5% from $7.01M a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of COCP and 1 opened new positions — a net loss of 3 holders — while 6 trimmed existing stakes and 7 added.
The largest buyer was Wasatch Advisors, adding an estimated $147K. The largest seller was Morgan Stanley, cutting an estimated $29.7K.
- 18 institutional investors held Cocrystal Pharma (COCP) as of Q2 2019, down from 21 in Q1 2019.
- Funds reported $6.41M of Cocrystal Pharma stock for Q2 2019, down 8.5% quarter-over-quarter.
- 1 fund opened new Cocrystal Pharma positions in Q2 2019 and 4 closed out, a net change of -3 holders.
- The largest Cocrystal Pharma buyer in Q2 2019 was Wasatch Advisors, an estimated $147K added.
- The largest Cocrystal Pharma seller in Q2 2019 was Morgan Stanley, an estimated $29.7K sold.
Based on aggregated 13F filings for Q2 2019.